Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of fecal microbiota transplantation with PD-1 antibody and chemotherapy in PD-L1-negative advanced lung adenocarcinoma
ChiCTR2300076829Phase 2Completed
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Feb 2021
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic fecal microbiota, cisplatin and pemetrexed in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Objective response rate and 6-month progression-free survival rate. Started Feb 2021; status: completed.
02
Drugs
allogeneic fecal microbiotacisplatinpemetrexed
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300076829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076829.